QuidelOrtho Corporation (QDEL)

QuidelOrtho is trading near the bottom of its 52-week range, at $11.91, after a sharp slide over the past year: the stock is down 45.59% over twelve months and sits below its 50-day and 200-day moving averages ($12.44 and $15.54). The most recent earnings report, dated November 3, 2026, showed adjusted EPS of $0.31 against an analyst estimate of $0.18, and the stock rose 1.85% in the next session. Revenue grew 2.77% year on year, yet that is slower than the sector median of 8.1%, and the company still posts a net loss margin of -39.20%. The question for investors is whether a profitable quarter on the adjusted basis can start to repair a business whose reported profitability and trend remain weak.

QuidelOrtho has beaten the EPS estimate in three of its last four reports, and the November 3, 2026 beat was the largest of the recent quarters that did not come with a sell-off: adjusted EPS of $0.31 against $0.18 expected, a 72.22% beat, followed by a 1.85% gain in the next session. The record is less tidy than it looks. The August 6, 2026 beat, where EPS of $0.13 beat a loss estimate of -$0.05, was followed by a 24.69% drop in the share price, and the May 5, 2026 miss, with EPS of -$0.04 against $0.36, came with a 6.00% fall. Across the last four reports, the share price was lower in the first session after three of them and higher after one.

The stock is 4.26% below its 50-day average and 23.36% below its 200-day average, and the 50-day average itself sits 19.95% below the 200-day average, a configuration that signals a long decline rather than a short pause. The one-year return of -45.59% and the one-week return of -17.00% show how far the price has been pushed down. The MACD line is negative and the 14-day RSI of 44.2 sits in the neutral zone, so momentum has stopped deteriorating faster but has not turned up.

At a price-to-sales ratio of 0.32, QDEL trades 90.7% below the sector median of 3.4, and its market capitalisation is $817.2M. The discount reflects the weak profitability: the net profit margin is -14.2%, return on equity is -19.29% against a sector median of 7.3%, and debt-to-equity stands at 1.74. Revenue grew 2.77% in the latest quarter year on year, slower than the sector median of 8.1%.

Insider activity over the last 18 months leans toward buying: eight open-market purchases worth $1.2M, against one sale worth $112K. Sales are often planned in advance, so the purchases carry more weight. Among three analysts with current ratings, one rates the stock buy or strong buy, one holds and one sells. Citigroup kept its Neutral rating on July 8, 2026, and JP Morgan kept its Underweight rating on July 1, 2026.

The base case is that QDEL keeps trading in a wide, low range while the business proves it can convert its operating margin of 2.28% into sustained earnings. The stock needs to reclaim the 50-day average at $12.44 and then the 20-day average near $12.82 before the trend picture improves; until it does, the price remains below both key averages. Analysts' estimates point to a sharp fall in fiscal 2026 EPS to $0.77 (down 63.5%) followed by a rebound to $1.32 in fiscal 2027 (up 70.1%), so the thesis depends on that recovery arriving. The median analyst target of $13.00 sits 9.2% above the price, with the range running from $12.00 to $20.00. A deterioration would look like another earnings miss, similar to the May 5, 2026 report, when EPS came in at -$0.04 against a $0.36 estimate. A better outcome would be a run of beats that holds up through the next sessions, which the stock failed to do after its August 6, 2026 beat.

Support sits at the 52-week low of $9.92, the nearest floor below the price and the level a fall would meet first. Resistance begins at the 50-day simple moving average of $12.44, which a rise would meet first, followed by the 20-day exponential moving average of $12.82. The 200-day simple moving average of $15.54 is the next hurdle above, and the 52-week high of $35.58 is the furthest reference point on the chart.